ClinicalTrials.gg
CompletedNCT02367014MMPOWERUpdated Dec 27, 2019Results posted

Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy

A Phase 1/2 interventional study of elamipretide (low dose) and elamipretide (intermediate dose) in Mitochondrial Myopathy, sponsored by Stealth BioTherapeutics Inc.. Completed at 4 sites in United States. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-12-27.

Sponsored by Stealth BioTherapeutics Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Mitochondrial Myopathies with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Mitochondrial Myopathies · United States.

Enrollment
8th of 12
36 · median 50
Started
2015
with 1 other
Phase 1/2
2 of 19
none open now
Registered
5th of 19
by date
Lead sponsor
4 of 19
Stealth BioTherapeutics Inc.

Among the 19 studies in Mitochondrial Myopathies with a site in United States, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2015, is one of 2 in phase 1/2, and was the 5th registered.

Mitochondrial Myopathies

46 studies on the registry are indexed under Mitochondrial Myopathies; 14 are open to participants now.

Browse Mitochondrial Myopathies studies →

Open to participants now

6 of the 19 studies in Mitochondrial Myopathies with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Mitochondrial Myopathies studies recruiting now, 8 (62%) set no upper age limit and 4 (31%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Mitochondrial Myopathies with a site in United States, or all of them as a file.
02

Study summary

Phase 1/2, multi-center, randomized, double-blind, multiple ascending dose, placebo-controlled study that enrolled 36 subjects with mitochondrial myopathy associated with genetically confirmed mitochondrial disease to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MTP-131 in this patient population.

Read the detailed description

This multi-center, randomized, double-blind, placebo-controlled study enrolled 36 subjects into 3 cohorts of 12 subjects each to evaluate treatment with 3 ascending doses of intravenous elamipretide (0.01, 0.10, and 0.25 mg/kg/hr infused for 2 hours). After each cohort, a Safety Monitoring Board (SMB) determined if dose escalation to the next higher dose of elamipretide was warranted. Each cohort went through 3 distinct periods: Screening, Treatment, and Follow-up.

The Screening Period started with informed consent and may have lasted up to 40 days. During this period, screening procedures to determine subject eligibility for the study occurred, including confirmation of disease, which incorporated a committee review of the investigator-submitted diagnosis and genetic results. The Treatment Period began on Day 1 (Visit 2) and lasted for 5 days (until Day 5 [Visit 6]). Within each cohort, 9 subjects were randomized to active drug and 3 subjects were randomized to placebo on Day 1 and subjects received treatment once a day for 5 consecutive days. Safety, tolerability, and efficacy measures were performed at pre-specified times. The Follow-up Period began at the time of discharge on Day 5. Subjects returned to the study center for the Follow-up Visit on Day 7 (+1 day).

03

Conditions studied

  • Mitochondrial Myopathy

Keywords

  • Mitochondrial Myopathy
  • Primary Mitochondrial Disease
  • Bendavia™
  • elamipretide
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of mitochondrial disease believed to impair the mitochondrial respiratory chain.
  • Eligibility requires prior genetic confirmation of mitochondrial disease.
  • Diagnosis of mitochondrial myopathy judged by the Investigators to be due to existing mitochondrial disease.
  • Must be able to complete a Screening Visit 6MWT.
  • (BMI) score >15.0 and \<35.0 kg/m2 at Screening Visit.
  • Women of must agree to use as specified in the protocol from the date they sign the ICF until two months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all study requirements.
  • Had any exclusionary Newcastle Mitochondrial Disease Adult Scale (NMDAS) scores at Screening Visit.
  • Hospitalized (admitted as in-patient) within 1 month prior to the Baseline Visit.
  • A history of type 1 diabetes mellitus (T1DM).
  • Uncontrolled Type 1 (T1DM) or Type 2 diabetes mellitus (T2DM), in the opinion of the investigator.
  • A \<45 mL/min as calculated by the Cockcroft Gault equation.
  • Requires pacemaker, defibrillator, or has undergone cardiac surgery within 2 years of Screening Visit.
  • elongation defined as a QTc >450 msec in male subjects and >480 msec in female subjects.
  • Uncontrolled hypertension (>160 mmHg systolic or >100 mmHg diastolic) at Screening Visit.
  • History of rhabdomyolysis defined as an acute rise in the serum creatine phosphokinase (CPK) value that, in the opinion of the investigator, caused symptoms.
  • Serum sodium more than 5 meq/L below the reference lower limit of normal at Screening Visit.
  • Participated in another interventional clinical trial within 3 months of the screening visit or is currently enrolled in a non-interventional clinical trial judged by the Investigator to be incompatible with the current trial.

    • Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Low Dose

    elamipretide 0.01 mg/kg/hr infused for 2 hours for 5 days

    Drug: elamipretide (low dose)

  • Experimental
    Intermediate dose

    elamipretide 0.10 mg/kg/hr infused for 2 hours for 5 days

    Drug: elamipretide (intermediate dose)

  • Experimental
    High dose

    elamipretide 0.25 mg/kg/hr infused for 2 hours for 5 days

    Drug: elamipretide (high dose)

  • Placebo comparator
    Placebo

    In each cohort, subjects received either IV elamipretide given once daily for 2 hours for 5 days or matching placebo.

    Drug: Placebo

Interventions

  • elamipretide (0.01 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days

    Also known as: MTP-131

  • elamipretide (0.10 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days

    Also known as: MTP-131

  • elamipretide (0.25 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days

    Also known as: MTP-131

  • DrugPlacebo

    placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days

06

What researchers measure

Primary outcomes

  1. Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT)

    Change in distance walked as measured by meters on the 6-minute walk test from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Assessed at Baseline, Day 5 (end-of-treatment visit)

Secondary outcomes

  1. Change in Maximum Oxygen Uptake (ml/kg/Min)

    Change in maximum oxygen uptake as measured by mL/kg/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  2. Change in Ventilatory Efficiency (VE/VCO2 Slope)

    Change in ventilatory efficiency as measured by the VE/VCO2 slope from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  3. Change in Aerobic Efficiency (ΔO2 Consumption/Δ Work Ratio)

    Change in aerobic efficiency as measured by ΔO2 consumption/Δ work ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  4. Change in Oxygen Utilization (ΔVO2/ΔlogVE Ratio)

    Change in oxygen utilization as measured by ΔVO2/ΔlogVE ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  5. Change in Oxygen Uptake Kinetics (Mean Response Time as Measured by Seconds)

    Change in oxygen uptake kinetics (mean response time) as measured by seconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  6. Change in Pre-exercise Lactate Levels (mg/dL)

    Change in pre-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  7. Change in Post-exercise Lactate Levels (mg/dL)

    Change in post-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  8. Change in Peak Respiratory Exchange Ratio (VCO2/VO2)

    Change in peak respiratory exchange ratio as measured by VCO2/VO2 from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  9. Change in Peak Respiratory Rate (Breaths/Min)

    Change in peak respiratory rate as measured by breaths/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  10. Change in Peak Ventilation (L/Min)

    Change in peak ventilation as measured by L/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  11. Change in Peak Heart Rate (Beats/Min)

    Change in peak heart rate as measured by beats per minute from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  12. Change in Peak Oxygen Saturation (% O2-saturated Hemoglobin)

    Change in peak oxygen saturation as measured by percentage of O2-saturated hemoglobin from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  13. Change in Peak Systolic Blood Pressure (mmHg)

    Change in peak systolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  14. Change in Peak Diastolic Blood Pressure (mmHg)

    Change in peak diastolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  15. Change in Peak Borg Dyspnea

    Change in peak Borg dyspnea as measured by 0-10 with 0 meaning no breathlessness and 10 meaning maximal breathlessness from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  16. Change in VO2 Anaerobic Threshold (mL)

    Change in VO2 anaerobic threshold as measured by mL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  17. Change in Watts

    Change in watts from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  18. Change in Temperature (°C)

    Change in temperature as measured by units of Celsius from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  19. Change in ECG-PR Interval (Msec)

    Change in PR interval as measured by ECG in milliseconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  20. Change in ECG-QRS Complex (Msec)

    Change in QRS complex as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  21. Change in ECG-QT Interval (Msec)

    Change in QT interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  22. Change in ECG-QTc Interval (Msec)

    Change in QTc interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  23. Number of Participants Who Had Suicide Ideation, Suicidal Behavior, or Non-suicidal Self-injurious Behavior Post-screening.

    Number of participants with suicide ideation, suicidal behavior, or non-suicidal self-injurious behavior post-screening as measured on Days 1-5, and Day 7 on the Columbia Suicide Severity Rating Scale (CSSRS). A yes/no binary response is utilized in the following ten categories: 1 - Wish to be Dead; 2 - Non-specific Active Suicidal Thoughts; 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; 5 - Active Suicidal Ideation with Specific Plan and Intent; 6 - Preparatory Acts or Behavior; 7 - Aborted Attempt; 8 - Interrupted Attempt; Category 9 - Actual Attempt (non-fatal); 10 - Completed Suicide. A yes/no binary response is also utilized in assessing self-injurious behavior without suicidal intent. A lower score means a better outcome whereas a higher score means a worse outcome.

    Time frame: Days 1-5 and Day 7.

  24. Change in Creatine Phosphokinase (IU/L)

    Change in Creatine Phosphokinase as measured by IU/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  25. Change in Alanine Aminotransferase (ALT) (U/L)

    Change in Alanine aminotransferase (ALT) as measured by (U/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  26. Change in Aspartate Aminotransferase (AST) (U/L)

    Change in aspartate aminotransferase (AST) as measured by U/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

  27. Change in Eosinophils (10^9 Cells/L)

    Change in eosinophils as measured by (10\^9 cells/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

    Time frame: Baseline, Day 5

07

Results

Posted Dec 27, 2019
Limitations and caveats
CPET was not performed on all subjects.Sensitivity analysis on change from Baseline in pre-and post-exercise lactate levels was not completed.Data from study sites were combined for efficacy and safety analyses.No site- effect analysis was performed.

Participant flow

Study Centers: Akron Children's Hospital; Massachusetts General Hospital; University of Pittsburgh School of Medicine; University of California, San Diego

Participant flow — Overall Study
MilestoneLow DoseIntermediate DoseHigh DosePlacebo
Started9999
Completed9999
Not completed0000

Outcome measures

PrimaryChange in Distance Walked (Meters) on the 6-minute Walk Test (6MWT)

Change in distance walked as measured by meters on the 6-minute walk test from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Assessed at Baseline, Day 5 (end-of-treatment visit)
Reported as:
Least squares mean · meters
Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT)
metersLow DoseIntermediate DoseHigh DosePlacebo
Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT)13.5 (-72 to 86)36.5 (-20 to 107)64.5 (4 to 133)20.4 (-37 to 90)
SecondaryChange in Maximum Oxygen Uptake (ml/kg/Min)

Change in maximum oxygen uptake as measured by mL/kg/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · ml/kg/min
Change in Maximum Oxygen Uptake (ml/kg/Min)
ml/kg/minLow DoseIntermediateHighPlacebo
Change in Maximum Oxygen Uptake (ml/kg/Min)0.35 ± 2.6172.36 ± 2.7140.64 ± 3.1212.14 ± 3.137
SecondaryChange in Ventilatory Efficiency (VE/VCO2 Slope)

Change in ventilatory efficiency as measured by the VE/VCO2 slope from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · VE/VCO2 slope
Change in Ventilatory Efficiency (VE/VCO2 Slope)
VE/VCO2 slopeLow DoseIntermediate DoseHigh DosePlacebo
Change in Ventilatory Efficiency (VE/VCO2 Slope)0.749 ± 2.9412-0.671 ± 5.4024-1.681 ± 3.2834-1.375 ± 5.5801
SecondaryChange in Aerobic Efficiency (ΔO2 Consumption/Δ Work Ratio)

Change in aerobic efficiency as measured by ΔO2 consumption/Δ work ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · ΔO2 consumption/Δwork ratio
Change in Aerobic Efficiency (ΔO2 Consumption/Δ Work Ratio)
ΔO2 consumption/Δwork ratioLow DoseIntermediate DoseHigh DosePlacebo
Change in Aerobic Efficiency (ΔO2 Consumption/Δ Work Ratio)-0.234 ± 4.34140.643 ± 2.7507-0.214 ± 1.97270.738 ± 3.5959
SecondaryChange in Oxygen Utilization (ΔVO2/ΔlogVE Ratio)

Change in oxygen utilization as measured by ΔVO2/ΔlogVE ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · ΔVO2/ΔlogVE ratio
Change in Oxygen Utilization (ΔVO2/ΔlogVE Ratio)
ΔVO2/ΔlogVE ratioLow DoseIntermediate DoseHigh DosePlacebo
Change in Oxygen Utilization (ΔVO2/ΔlogVE Ratio)-118.87 ± 229.105184.99 ± 410.09390.13 ± 116.281166.50 ± 479.145
SecondaryChange in Oxygen Uptake Kinetics (Mean Response Time as Measured by Seconds)

Change in oxygen uptake kinetics (mean response time) as measured by seconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · seconds
Change in Oxygen Uptake Kinetics (Mean Response Time as Measured by Seconds)
secondsLow DoseIntermediateHighPlacebo
Change in Oxygen Uptake Kinetics (Mean Response Time as Measured by Seconds)6.40 ± 11.402-2.49 ± 26.830-9.75 ± 26.288-7.47 ± 14.357
SecondaryChange in Pre-exercise Lactate Levels (mg/dL)

Change in pre-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · mg/dL
Change in Pre-exercise Lactate Levels (mg/dL)
mg/dLLow DoseIntermediate DoseHigh DosePlacebo
Change in Pre-exercise Lactate Levels (mg/dL)3.4 ± 9.0013.8 ± 18.300.4 ± 10.254.4 ± 14.06
SecondaryChange in Post-exercise Lactate Levels (mg/dL)

Change in post-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · mg/dL
Change in Post-exercise Lactate Levels (mg/dL)
mg/dLLow DoseIntermediate DoseHigh DosePlacebo
Change in Post-exercise Lactate Levels (mg/dL)6.9 ± 11.8710.6 ± 42.934.3 ± 22.108.4 ± 13.21
SecondaryChange in Peak Respiratory Exchange Ratio (VCO2/VO2)

Change in peak respiratory exchange ratio as measured by VCO2/VO2 from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · VCO2/VO2 ratio
Change in Peak Respiratory Exchange Ratio (VCO2/VO2)
VCO2/VO2 ratioLow DoseIntermediate DoseHigh DosePlacebo
Change in Peak Respiratory Exchange Ratio (VCO2/VO2)0.109 ± 0.07410.114 ± 0.18030.010 ± 0.05610.133 ± 0.1297
SecondaryChange in Peak Respiratory Rate (Breaths/Min)

Change in peak respiratory rate as measured by breaths/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · breaths/min
Change in Peak Respiratory Rate (Breaths/Min)
breaths/minLow DoseIntermediate DoseHigh DosePlacebo
Change in Peak Respiratory Rate (Breaths/Min)1.4 ± 6.54-0.7 ± 5.720.9 ± 6.248.2 ± 5.26
SecondaryChange in Peak Ventilation (L/Min)

Change in peak ventilation as measured by L/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · L/min
Change in Peak Ventilation (L/Min)
L/minLow DoseIntermediate DoseHigh DosePlacebo
Change in Peak Ventilation (L/Min)2.70 ± 8.6928.87 ± 7.9752.49 ± 8.3038.47 ± 8.564
SecondaryChange in Peak Heart Rate (Beats/Min)

Change in peak heart rate as measured by beats per minute from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · beats/min
Change in Peak Heart Rate (Beats/Min)
beats/minLow DoseIntermediate DoseHigh DosePlacebo
Change in Peak Heart Rate (Beats/Min)10.1 ± 11.1516.7 ± 13.024.5 ± 9.583.8 ± 7.85
SecondaryChange in Peak Oxygen Saturation (% O2-saturated Hemoglobin)

Change in peak oxygen saturation as measured by percentage of O2-saturated hemoglobin from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · percentage of O2-saturated hemoglobin
Change in Peak Oxygen Saturation (% O2-saturated Hemoglobin)
percentage of O2-saturated hemoglobinLow DoseIntermediate DoseHigh DosePlacebo
Change in Peak Oxygen Saturation (% O2-saturated Hemoglobin)0.0 ± 1.690.1 ± 1.070.6 ± 0.740.3 ± 1.60
SecondaryChange in Peak Systolic Blood Pressure (mmHg)

Change in peak systolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · mmHg
Change in Peak Systolic Blood Pressure (mmHg)
mmHgLow DoseIntermediate DoseHigh DosePlacebo
Change in Peak Systolic Blood Pressure (mmHg)16.7 ± 21.00-1.5 ± 36.4716.0 ± 12.71-2.7 ± 21.84
SecondaryChange in Peak Diastolic Blood Pressure (mmHg)

Change in peak diastolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · mmHg
Change in Peak Diastolic Blood Pressure (mmHg)
mmHgLow DoseIntermediate DoseHigh DosePlacebo
Change in Peak Diastolic Blood Pressure (mmHg)0.6 ± 12.67-1.4 ± 11.13-2.5 ± 9.07-6.6 ± 12.74
SecondaryChange in Peak Borg Dyspnea

Change in peak Borg dyspnea as measured by 0-10 with 0 meaning no breathlessness and 10 meaning maximal breathlessness from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · Units on a scale
Change in Peak Borg Dyspnea
Units on a scaleLow DoseIntermediate DoseHigh DosePlacebo
Change in Peak Borg Dyspnea-2.00 ± 2.00-2.2 ± 2.23-1.4 ± 1.30-0.4 ± 1.70
SecondaryChange in VO2 Anaerobic Threshold (mL)

Change in VO2 anaerobic threshold as measured by mL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · mL
Change in VO2 Anaerobic Threshold (mL)
mLLow DoseIntermediate DoseHigh DosePlacebo
Change in VO2 Anaerobic Threshold (mL)30.00 ± 83.9310.8 ± 80.351.6 ± 42.1742.0 ± 51.89
SecondaryChange in Watts

Change in watts from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · watts
Change in Watts
wattsLow DoseIntermediate DoseHigh DosePlacebo
Change in Watts9.6 ± 14.1513.9 ± 12.485.4 ± 10.034.4 ± 11.87
SecondaryChange in Temperature (°C)

Change in temperature as measured by units of Celsius from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · °C
Change in Temperature (°C)
°CLow DoseIntermediate DoseHigh DosePlacebo
Change in Temperature (°C)-0.3 ± 0.540.2 ± 0.420.1 ± 0.280.0 ± 0.67
SecondaryChange in ECG-PR Interval (Msec)

Change in PR interval as measured by ECG in milliseconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · msec
Change in ECG-PR Interval (Msec)
msecLow DoseIntermediate DoseHigh DosePlacebo
Change in ECG-PR Interval (Msec)-3.2 ± 7.778.3 ± 7.059.1 ± 9.55-1.6 ± 15.61
SecondaryChange in ECG-QRS Complex (Msec)

Change in QRS complex as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · msec
Change in ECG-QRS Complex (Msec)
msecLow DoseIntermediate DoseHigh DosePlacebo
Change in ECG-QRS Complex (Msec)1.2 ± 7.142.3 ± 6.56-2.2 ± 8.860.8 ± 5.78
SecondaryChange in ECG-QT Interval (Msec)

Change in QT interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · msec
Change in ECG-QT Interval (Msec)
msecLow DoseIntermediate DoseHigh DosePlacebo
Change in ECG-QT Interval (Msec)-6.0 ± 30.53-4.8 ± 12.94-16.7 ± 81.02-1.3 ± 18.49
SecondaryChange in ECG-QTc Interval (Msec)

Change in QTc interval as measured by ECG in msec from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · msec
Change in ECG-QTc Interval (Msec)
msecLow DoseIntermediate DoseHigh DosePlacebo
Change in ECG-QTc Interval (Msec)3.4 ± 20.171.3 ± 20.24-23.2 ± 77.536.7 ± 17.28
SecondaryNumber of Participants Who Had Suicide Ideation, Suicidal Behavior, or Non-suicidal Self-injurious Behavior Post-screening.

Number of participants with suicide ideation, suicidal behavior, or non-suicidal self-injurious behavior post-screening as measured on Days 1-5, and Day 7 on the Columbia Suicide Severity Rating Scale (CSSRS). A yes/no binary response is utilized in the following ten categories: 1 - Wish to be Dead; 2 - Non-specific Active Suicidal Thoughts; 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; 5 - Active Suicidal Ideation with Specific Plan and Intent; 6 - Preparatory Acts or Behavior; 7 - Aborted Attempt; 8 - Interrupted Attempt; Category 9 - Actual Attempt (non-fatal); 10 - Completed Suicide. A yes/no binary response is also utilized in assessing self-injurious behavior without suicidal intent. A lower score means a better outcome whereas a higher score means a worse outcome.

Time frame:
Days 1-5 and Day 7.
Reported as:
Count of participants · Participants
Number of Participants Who Had Suicide Ideation, Suicidal Behavior, or Non-suicidal Self-injurious Behavior Post-screening.
ParticipantsLow DoseIntermediate DoseHigh DosePlacebo
Number of Participants Who Had Suicide Ideation, Suicidal Behavior, or Non-suicidal Self-injurious Behavior Post-screening.0000
SecondaryChange in Creatine Phosphokinase (IU/L)

Change in Creatine Phosphokinase as measured by IU/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · IU/L
Change in Creatine Phosphokinase (IU/L)
IU/LLow DoseIntermediate DoseHigh DosePlacebo
Change in Creatine Phosphokinase (IU/L)-24.8 ± 25.10-161.7 ± 176.49-101.2 ± 149.07-154.9 ± 232.99
SecondaryChange in Alanine Aminotransferase (ALT) (U/L)

Change in Alanine aminotransferase (ALT) as measured by (U/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · U/L
Change in Alanine Aminotransferase (ALT) (U/L)
U/LLow DoseIntermediate DoseHigh DosePlacebo
Change in Alanine Aminotransferase (ALT) (U/L)19.3 ± 42.24-3.0 ± 4.92-5.3 ± 3.281.1 ± 5.80
SecondaryChange in Aspartate Aminotransferase (AST) (U/L)

Change in aspartate aminotransferase (AST) as measured by U/L from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · U/L
Change in Aspartate Aminotransferase (AST) (U/L)
U/LLow DoseIntermediate DoseHigh DosePlacebo
Change in Aspartate Aminotransferase (AST) (U/L)5.6 ± 9.93-2.2 ± 10.38-12.6 ± 18.08-4.4 ± 13.07
SecondaryChange in Eosinophils (10^9 Cells/L)

Change in eosinophils as measured by (10\^9 cells/L) from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit).

Time frame:
Baseline, Day 5
Reported as:
Mean · 10^9 cells/L
Change in Eosinophils (10^9 Cells/L)
10^9 cells/LLow DoseIntermediate DoseHigh DosePlacebo
Change in Eosinophils (10^9 Cells/L)0.06 ± 0.0730.08 ± 0.097-0.01 ± 0.0640.04 ± 0.088

Adverse events

Collected over 7 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose0/9 (0%)0/9 (0%)7/9 (77.8%)
Intermediate Dose0/9 (0%)0/9 (0%)7/9 (77.8%)
High Dose0/9 (0%)0/9 (0%)5/9 (55.6%)
Placebo0/9 (0%)0/9 (0%)5/9 (55.6%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventLow DoseIntermediate DoseHigh DosePlacebo
HeadacheNervous system disorders1/91/92/92/9
DizzinessNervous system disorders2/91/90/90/9
Abdominal painGastrointestinal disorders0/92/90/90/9
FlatulenceGastrointestinal disorders1/90/90/91/9
Muscle spasmsMusculoskeletal and connective tissue disorders1/90/90/91/9
ConstipationGastrointestinal disorders0/90/90/91/9
NauseaGastrointestinal disorders0/91/90/90/9
Injection site bruisingGeneral disorders1/90/90/90/9
ThirstGeneral disorders0/90/90/91/9
Vessel puncture site haemorrhageGeneral disorders0/91/90/90/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Low DoseIntermediate DoseHigh DosePlaceboTotal
Mean40.8 ± 11.3245.0 ± 14.0942.3 ± 16.8441.9 ± 15.8342.5 ± 14.12
Sex: Female, Male
Sex: Female, Male(Participants)Low DoseIntermediate DoseHigh DosePlaceboTotal
Female786930
Male21306
08

Study locations

4 sites
  • University of California
    San Diego, California 92093, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Children's Hospital of Pittsburg of UPMC
    Pittsburgh, Pennsylvania 15213, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2019, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2015
First posted
Feb 20, 2015
Start
Feb 2015
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Results first posted
Dec 27, 2019
Last update
Dec 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02367014
Responsible party
Sponsor
First posted
Feb 20, 2015
Start date
Feb 2015
Primary completion
Apr 2016
Completion
Apr 2016
Results posted
Dec 27, 2019
Last update
Dec 27, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion